Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.)
Filed by the Registrant  X
Filed by a Party other than the Registrant  
Check the appropriate box:
 Preliminary Proxy Statement
 Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
 Definitive Proxy Statement
X
 Definitive Additional Materials
 Soliciting Material under §240.14a-12
DAVITA INC.
(Name of Registrant as Specified In Its Charter)
 
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
XNo fee required.
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1)Title of each class of securities to which transaction applies:
     
(2)Aggregate number of securities to which transaction applies:
     
(3)Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
     
(4)Proposed maximum aggregate value of transaction:
     
(5)Total fee paid:
     
Fee paid previously with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
(1)Amount Previously Paid:
     
(2)Form, Schedule or Registration Statement No.:
     
(3)Filing Party:
     
(4)Date Filed:
     





 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 Form 8-K 

 CURRENT REPORT
 Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (date of earliest event reported): May 19, 2021
 

 
DAVITA INC.
(Exact name of registrant as specified in its charter)
 

 
DE1-1410651-0354549
(State or other jurisdiction
of incorporation)
(Commission File Number)(IRS Employer
Identification No.)
 
2000 16th Street
Denver,CO80202
(Address of principal executive offices including Zip Code)
 
(720) 631-2100
(Registrant’s telephone number, including area code)
 
Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 240.425)
 
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class: Trading symbol(s):Name of each exchange on which registered:
Common Stock, $0.001 par value DVANew York Stock Exchange



Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 19, 2021, Shawn Guertin, member of the Board of Directors (the "Board") of DaVita Inc. (the "Company"), notified the Board that he will step down from the Board, as a member and chair of the Audit Committee of the Board (the "Audit Committee") and as a member of the Nominating and Governance Committee of the Board (the "Nominating and Governance Committee") due to anticipated increased time commitments associated with his pending new position as executive vice president and chief financial officer of CVS Health. Mr. Guertin therefore will no longer be considered a director nominee for the purposes of the election of directors at the Company's 2021 Annual Meeting of Stockholders to be held on June 10, 2021. Mr. Guertin's decision to step down is not the result of any disagreement with the Company and was effective as of May 19, 2021.

In connection with the foregoing, the Board approved a reduction in the size of the Board from nine to eight members. Barbara Desoer, member of the Board and Compliance and Quality Committee of the Board (the "Compliance and Quality Committee"), and chair of the Compensation Committee of the Board (the "Compensation Committee"), was appointed to serve as a member of the Audit Committee and will no longer serve on the Compliance and Quality Committee. Paula Price, member of the Board, Compliance and Quality Committee and Audit Committee was appointed to serve as chair of the Audit Committee. John Nehra, member of the Board, Compensation Committee and Audit Committee, was appointed to serve on the Nominating and Governance Committee. All of the actions described in this paragraph were effective as of May 19, 2021. The Board is engaged in an ongoing process to select one or more new directors.







SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
DAVITA INC.
Date: May 21, 2021By:/s/ Kathleen A. Waters
Kathleen A. Waters
Chief Legal and Public Affairs Officer